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STUDY QUESTION: What is the recommended assessment and management of infertile women with polycystic ovary syndrome
(PCOS), based on the best available evidence, clinical expertize and consumer preference?
SUMMARY ANSWER: International evidence-based guidelines, including 44 recommendations and practice points, addressed prioritized
questions to promote consistent, evidence-based care and improve the experience and health outcomes of infertile women with PCOS.
WHAT IS KNOWN ALREADY: Previous guidelines on PCOS lacked rigorous evidence-based processes, failed to engage consumer and
multidisciplinary perspectives or were outdated. The assessment and management of infertile women with PCOS are inconsistent. The needs
of women with PCOS are not being adequately met and evidence practice gaps persist.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
PARTICIPANTS/MATERIALS, SETTING, METHODS: Governance included a six continent international advisory and a project
board, a multidisciplinary international guideline development group (GDG), consumer and translation committees. Extensive health profes-
sional and consumer engagement informed the guideline scope and priorities. The engaged international society-nominated panel included
endocrinology, gynaecology, reproductive endocrinology, obstetrics, public health and other experts, alongside consumers, project manage-
ment, evidence synthesis and translation experts. Thirty-seven societies and organizations covering 71 countries engaged in the process.
Extensive online communication and two face-to-face meetings over 15 months addressed 19 prioritized clinical questions involving nine
evidence-based reviews and 10 narrative reviews. Evidence-based recommendations (EBRs) were formulated prior to consensus voting
within the guideline panel.
STUDY DESIGN, SIZE, DURATION: International evidence-based guideline development engaged professional societies and consumer
organizations with multidisciplinary experts and women with PCOS directly involved at all stages. A (AGREE) II-compliant processes were fol-
lowed, with extensive evidence synthesis. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) frame-
work was applied across evidence quality, desirable and undesirable consequences, feasibility, acceptability, cost, implementation and
ultimately recommendation strength. The guideline was peer-reviewed by special interest groups across our partner and collaborating soci-
eties and consumer organizations, was independently assessed against AGREE II criteria and underwent methodological review. This guideline
was approved by all members of the GDG and has been approved by the NHMRC.
MAIN RESULTS AND THE ROLE OF CHANCE: The quality of evidence (QOE) for the EBRs in the assessment and management of
infertility in PCOS included very low (n = 1), low (n = 9) and moderate (n = 4) quality with no EBRs based on high-quality evidence. The
guideline provides 14 EBRs, 10 clinical consensus recommendations (CCRs) and 20 clinical practice points on the assessment and manage-
ment of infertility in PCOS. Key changes in this guideline include emphasizing evidence-based fertility therapy, including cheaper and safer fer-
tility management.
LIMITATIONS, REASONS FOR CAUTION: Overall evidence is generally of low to moderate quality, requiring significantly greater
research in this neglected, yet common condition. Regional health systems vary and a process for adaptation of this guideline is provided.
WIDER IMPLICATIONS OF THE FINDINGS: The international guideline for the assessment and management of infertility in PCOS
provides clinicians with clear advice on best practice based on the best available evidence, expert multidisciplinary input and consumer prefer-
ences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation program supports
the guideline with an integrated evaluation program.
STUDY FUNDING/COMPETING INTEREST(S): The guideline was primarily funded by the Australian National Health and Medical
Research Council of Australia (NHMRC) supported by a partnership with ESHRE and the American Society for Reproductive Medicine
(ASRM). GDG members did not receive payment. Travel expenses were covered by the sponsoring organizations. Disclosures of conflicts of
interest were declared at the outset and updated throughout the guideline process, aligned with NHMRC guideline processes. Dr Costello
has declared shares in Virtus Health and past sponsorship from Merck Serono for conference presentations. Prof. Norman has declared a
minor shareholder interest in the IVF unit Fertility SA, travel support from Merck and grants from Ferring. Prof. Norman also has scientific
advisory board duties for Ferring. The remaining authors have no conflicts of interest to declare.
This article was not externally peer-reviewed by Human Reproduction Open.
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WHATDOES THIS MEAN FOR PATIENTS?
This guideline aims to optimize evidence-based, consistent care that meets the needs and improves the quality of life of infertile women with
polycystic ovary syndrome (PCOS). The guideline and translation program were developed with full consumer participation at all stages, target-
ing areas and outcomes of priority for women with PCOS. The overall aim is to support women and their healthcare providers to optimize the
assessment and management of infertility in PCOS. There is an emphasis on partnership in care and empowerment of women with PCOS.
Personal characteristics, preferences, culture and values are considered. With effective translation, the guideline and suite of health professional
and consumer resources will address the gaps and priorities identified by women with PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy
affecting reproductive aged women, with a prevalence of between 8% and
13% depending on the population studied and definitions used. PCOS is
complex with reproductive, metabolic and psychological features (Teede
et al., 2010). Infertility is a prevalent presenting feature of PCOS with ~75%
of these women suffering infertility due to anovulation, making PCOS by far
the most common cause of anovulatory infertility (Homburg, 2004).
The treatment of infertility in PCOS includes lifestyle changes (diet
and exercise), pharmacological therapies (oral agents such as clomi-
phene citrate, letrozole or metformin or injectable agents such as
gonadotrophins), surgical therapy (laparoscopic ovarian surgery) or
IVF (Costello et al., 2012). IVM has been proposed to offer a promising
alternative to conventional IVF (Chian, 2004).
Current guidelines on PCOS either are limited in breadth, do not
follow rigorous best practice in development, have not involved consu-
mers or are outdated (Teede et al., 2011; Legro et al., 2013; Conway
et al., 2014; Goodman et al., 2015; Balen et al., 2016) resulting in
inconsistent guidance for clinicians and women alike. To address these
identified gaps, the first ever international evidence-based guideline for
the assessment and management of PCOS was recently published and
it integrates the best available evidence with international, multidiscip-
linary clinical expertize and consumer preferences in order to provide
health professionals, consumers and policy makers with guidance
(International Evidence-Based Guidelines for the Assessment and
Management of Polycystic Ovary Syndrome, 2018; Teede et al.,
2018a,b,c). This current paper is restricted to the section of the guide-
line addressing the assessment and management of infertility in PCOS.
The clinical context and evidence informing the infertility section of the
guideline are published in the full guideline (International Evidence-
Based Guidelines for the Assessment and Management of Polycystic
Ovary Syndrome, 2018).
Materials andMethods
Best practice evidence-based guideline development methodology was
applied and are detailed in the full guideline (International Evidence-Based
Guidelines for the Assessment and Management of Polycystic Ovary
Syndrome, 2018). In short, the international evidence-based guideline
development engaged health professional societies and consumer organi-
zations, with multidisciplinary experts and women with PCOS directly
involved at all stages.
A six continent international advisory and a project board, a multidiscip-
linary international guideline development group (GDG), plus consumer
and translation committees provided governance. The engaged inter-
national society-nominated panel provided experts in endocrinology,
gynaecology, reproductive endocrinology, obstetrics and public health,
alongside consumers, project management, evidence synthesis and transla-
tion experts. Thirty-seven societies and organizations representing 71
countries were engaged in a 15-month process that addressed 19 priori-
tized clinical questions encompassing 9 evidence-based reviews and 10
narrative reviews. Appraisal of Guidelines for Research and Evaluation
(AGREE) II-compliant processes were followed, with extensive evidence
synthesis. The Grading of Recommendations, Assessment, Development
and Evaluation (GRADE) framework was applied across evidence quality,
desirable and undesirable consequences, feasibility, acceptability, cost,
implementation and, ultimately, recommendation strength. Evidence-
based recommendations (EBRs) were formulated prior to consensus vot-
ing within the guideline panel.
Interpreting the recommendations
The category of the recommendations includes evidence-based or consen-
sus recommendations and has accompanying relevant clinical practice
points (CPP), as described in Table I. When sufficient evidence was avail-
able in PCOS, an EBR was made, where there was insufficient evidence in
PCOS, evidence in general or other relevant populations was also con-
sidered and if appropriate and there was consensus, the GDG made clin-
ical consensus recommendations (CCRs). CPP highlighted important
clinical and implementation issues arising from GDG consideration of
evidence-based or CCR and from peer review.
The recommendation terms include ‘should’, ‘could’ and ‘should not’.
These terms are informed by the nature of the recommendation (evidence
or consensus), the GRADE framework and evidence quality and are inde-
pendent descriptors reflecting the judgement of the multidisciplinary GDG
including consumers. They refer to overall interpretation and practical
application of the recommendation, balancing benefits and harms. ‘Should’
is used where benefits of the recommendation exceed harms, and where
the recommendation can be trusted to guide practice. ‘Could’ is used
where either the QOE was limited or the available studies demonstrate lit-
tle clear advantage of one approach over another, or the balance of bene-
fits to harm was unclear. ‘Should not’ is used where there is either a lack of
appropriate evidence, or the harms may outweigh the benefits.
The GRADE of the recommendation is determined by the GDG from
structured consideration of the GRADE framework (National Health and
Medical Research Council, 2009) including desirable effects, undesirable
effects, balance of effects, resource requirements and cost effectiveness,
equity, acceptability and feasibility, and includes: *Conditional recommen-
dation against the option; **Conditional recommendation for either the
option or the comparison; ***Conditional recommendation for the option;
**** Strong recommendation for the option.
QOE is categorized (see Table II) according to:
- information about the number and design of studies addressing the
outcome;
- judgments about the quality of the studies and/or synthesized evidence,
such as risk of bias, inconsistency, indirectness, imprecision and any other
considerations that may influence the QOE: key statistical data;
- and classification of the importance of the outcomes.
The QOE reflects the extent to which our confidence in an estimate of
the effect is adequate to support a particular recommendation (National
Health and Medical Research Council, 2009) and was largely determined
by the expert evidence synthesis team.
Table I Categories of the polycystic ovary syndrome
guideline recommendations.
EBR Evidence-based recommendations: evidence sufficient to inform
a recommendation made by GDG.
CCR Clinical consensus recommendations: in the absence of
evidence, a clinical consensus recommendation has been made
by the GDG.
CPP Clinical practice points: evidence not sought. A practice point
has been made by the GDG where important issues arose from
discussion of evidence-based or clinical consensus
recommendations.
GDG: the guideline development group (Teede et al., 2018a,b,c).
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GRADE note that QOE is a continuum; any discrete categorization
involves a degree of arbitrariness. Nevertheless, advantages of simplicity,
transparency, and vividness outweigh these limitations (National Health
and Medical Research Council, 2009). CCR are not rated in QOE (as no
evidence was found) (see below) and CCP do not have a ‘GRADE’ rating
as CPPs arose from discussion of evidence-based or CCR (Table I).
The meaning or interpretation of the GRADE of recommendations
according to strength (strong or conditional [or weak]) can be seen in
Table III.
Results
The guideline section addressing the assessment and management of
infertile women with PCOS includes 14 EBRs, 10 CCR and 20 CPP.
The QOE for the EBRs included very low (n = 1), low (n = 9), and
moderate (n = 4) quality, with no EBRs based on high-quality evidence.
The GRADE of recommendations included the following: *Conditional
recommendation against the option (n = 2, all CCRs); **Conditional
recommendation for either the option or the comparison (n = 1, a
CCR); ***Conditional recommendation for the option (n = 15, 11
EBRs and four CCRs); and **** Strong recommendation for the option
(n = 3, all EBRs).
The recommendations for the assessment and treatment of infertil-
ity can be found in the full guideline (International Evidence-Based
Guidelines for the Assessment and Management of Polycystic Ovary
Syndrome, 2018). The comprehensive evidence reviews, profiles and
GRADE frameworks supporting each recommendation, can be found
in the supplementary Technical report (2018) at https://www.
monash.edu/__data/assets/pdf_file/0020/1412282/PCOS-
Guideline_Technical-report.pdf. A summary of the recommendations
for the assessment and treatment of infertility can be seen in Fig. 1
Tubal patency testing
Clinical question
Should women with PCOS and infertility due to anovulation alone with
normal semen analysis have tubal patency testing prior to starting ovu-
lation induction with timed intercourse or IUI treatment or delayed
tubal patency testing?
Table II Quality (certainty) of evidence categories
adapted from the grading of recommendations,
assessment, development and evaluation frameworka.
High ⊕⊕⊕⊕ Very confident that the true effect lies close to
that of the estimate of the effect
Moderate ⊕⊕⊕o Moderate confidence in the effect estimate: the
true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is
substantially different
Low ⊕⊕oo Limited confidence in the effect estimate: the
true effect may be substantially different from the
estimate of the effect
Very Low ⊕ooo Very little confidence in the effect estimate: the
true effect is likely to be substantially different
from the estimate of effect
Teede et al. (2018a,b,c).
aAdapted from the grading of recommendations, assessment, development, and
evaluation framework (GRADE) (National Health and Medical Research Council
2009)
.............................................................................................................................................................................................
Table III Interpretation of the strength of the GRADE of recommendations according to consumers, health










the option or the comparison
CPPb
Consumers Most people in your situation
would want the
recommended course of
action and only a small
proportion would not.
The majority of people in your
situation would want the
recommended course of action, but
some would not.
There is considerable lack of clarity
over whether the majority of people
in your situation would want the
recommended course of action or
not.
Clinicians, patients and policy
makers are informed on the





Most patients should receive
the recommended course of
action.
Recognize that different choices will be
appropriate for different patients and
that greater effort is needed with
individuals to arrive at management
decisions consistent with values and
preferences. Decision aids and shared
decision making are important here.
Policy
makers
The recommendation can be
adopted as policy in most
situations.
Policy making needs to consider
perspectives and involvement of
diverse stakeholders.
Policy decisions remain unclear.
aStrong recommendations based on high-quality evidence will apply to most patients for whom these recommendations are made, but they may not apply to all patients in all condi-
tions; no recommendation can take into account all of the often-compelling unique features of individual patients and clinical circumstances.
bA CPP is developed by the GDG to support recommendations. Advice can be provided to enhance shared decision making, and on factors to be considered in implementing a spe-
cific test or intervention.
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Figure 1 Practitioner support tool Algorithm 1: Screening, diagnostic assessment risk assessment and lifestage. ©International Evidence-based
Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2018, Helena Teede et al. Monash University (monash.edu/medicine/
sphpm/mchri/pcos), 2018, by permission of Monash University, on behalf of the NHMRC Centre for Research Excellence in PCOS. This image/con-
tent is not covered by the terms of the Creative Commons licence of this publication. For permission to reuse, please contact the rights holder.
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Clinical need for the question
One of the leading causes of female infertility is tubal pathology, potentially
affecting around 30% of infertile women (Al Subhi et al., 2013). The diag-
nostic assessment of infertility often includes tubal testing by hysterosalpin-
gography or laparoscopy as outlined in the World Health Organization
(WHO) evidence report on infertility management in PCOS. PCOS is the
most frequent cause of anovulation in infertile women and ovulation induc-
tion is the most common treatment, however, there is little information
about the prevalence of tubal pathology or the need for IUI with normal
semen analysis in infertile women with PCOS.
Summary of narrative evidence
A systematic review was not conducted to answer this question and
this was reviewed narratively based on clinical expertize. There is no
evidence to support that hydrosalpinges or other Fallopian tube disor-
ders are more frequent in PCOS women (Broeze et al., 2011). Yet the
assessment of tubal patency is considered in infertility workup, as out-
lined in the WHO evidence report on infertility treatment in PCOS.
Whilst adverse effects from this intervention are not common, false
positives have been described and tubal patency testing may be more
appropriate when targeted to those at increased risk of tubal infertility
Figure 1 Continued
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(Schankath et al., 2012). In this context, consideration of risks for
tubal pathology are clinically appropriate including: previous
abdominal or pelvic sepsis, previous pelvic and/or abdominal
surgery, cases of recurrent acute pelvic pain (Luttjeboer et al.,
2009), history of sexual transmitted diseases or pelvic inflammatory
disease, or endometriosis.
Figure 1 Continued
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Justification
If the patient has a clinical history of factors associated with tubal infertil-
ity, it was deemed that hysterosalpingography could be considered, con-
sistent with routine assessment of infertility. Hysterosalpingography
requires dilation of the cervix that generally produces some discomfort,
false positives are described and other related complications are uncom-
mon. A lack of evidence to guide practice was noted in PCOS when
considering these recommendations, however general population
approaches were judged as applicable in this population, where other
risk factors are present.
Ovulation induction principles
In reviewing the literature on pharmacological treatment for ovulation induc-
tion, general principles emerged that apply across all recommendations.
These have been extracted into a set of CPP to inform women and guide
health professionals when considering or recommending pharmacological
therapy for ovulation induction in PCOS. These practice points apply to all
pharmacological treatments prioritized and addressed in the guidelines. In




In women with PCOS, are aromatase inhibitors (AI) effective for
improving fertility outcomes?
Clinical need for the question
AI are effective as ovulation-inducing agents, including letrozole and ana-
strozole, with letrozole being the most widely used (Mitwally and
Casper, 2001; Elizur and Tulandi, 2008). These agents prevent the
aromatase-induced conversion of androgens to oestrogens, including in
the ovary. Yet their mechanisms of ovulation induction are unknown,
however they increase the secretion of FSH thereby stimulating ovarian
follicle development and maturation (Adashi, 1984). The efficacy,
adverse effects and overall role of letrozole in oral ovulation induction
have remained controversial.
Summary of systematic review evidence
AI versus placebo. One small RCT (Kamath et al., 2010) with a low
risk of bias compared letrozole to placebo in women with clomiphene
citrate-resistant PCOS and found that letrozole was better than pla-
cebo for ovulation rate per patient (Letrozole: 6 patients/18 patients
(33.33%), Placebo: 0 patients/18 patients (0%), P = 0.006) but there
was no difference between letrozole and placebo for pregnancy rate
per patient or live birth rate per patient. It is important to note that
the findings from this study are of low certainty due to serious risk of
imprecision. This study was included in a meta-analysis by Franik et al.
(2014) and Misso et al. (2012), however since there is only one study,
the meta-analyses do not provide additional evidence.
AI versus clomiphene citrate. Thirteen RCTs compared letrozole with
clomiphene citrate. Seven of these RCTs had a high risk of bias (Atay
et al., 2006; Zeinalzadeh et al., 2010; Sheikh-El-Arab Elsedeek and
Elmaghraby, 2011; Banerjee Ray et al., 2012; Kar, 2012; Nazik and
Kumtepe, 2012; Selim and Borg, 2012), two had a moderate risk of
bias (Begum et al., 2009; Dehbashi et al., 2009) and four had a low risk
of bias (Bayar et al., 2006; Badawy et al., 2009; Roy et al., 2012; Legro
et al., 2014a,b). Upon meta-analysis, we found that letrozole was bet-
ter than clomiphene citrate for ovulation rate per patient, pregnancy
rate per patient and live birth rate per patient. There was no difference
between letrozole and clomiphene citrate for multiple pregnancy rate
per patient and miscarriage rate per patient. When subgroup analysis
was conducted for studies that included women with PCOS who were
therapy naïve, there was no difference between the two interventions
for any outcome although we note that for pregnancy rate per patient
the odds ratio (OR) 1.68 [95% CI 0.96, 2.94] had an I2 of 0% and a P
value of 0.07.
AI versus clomiphene citrate + metformin. One RCT with moderate
risk of bias found that there is no statistical difference between letro-
zole and clomiphene citrate plus metformin for ovulation rate per
cycle, pregnancy rate per cycle, miscarriage rate per pregnancy and
multiple pregnancy rate per pregnancy in clomiphene citrate-resistant
women with PCOS (Abu Hashim et al., 2010b). This study was
included in a meta-analysis by Franik et al. (2014) and Misso et al.
(2012), however since there is only one study, the meta-analysis does
not provide additional evidence.
AI versus laparoscopic ovarian surgery. Three RCTs with low risk of
bias (Abu Hashim et al., 2010a, Abdellah, 2011; Ibrahim et al., 2017)
compared letrozole to laparoscopic ovarian surgery and found that
there was insufficient evidence of a difference between letrozole and
laparoscopic ovarian surgery. One of the RCTs in 147 women with
clomiphene citrate resistance found that letrozole was better than lap-
aroscopic ovarian surgery for ovulation rate per cycle (Abdellah,
2011), however the evidence is of low certainty. The systematic
review by Farquhar et al. (2012) combined these studies in meta-
analysis for pregnancy rate per patient, multiple pregnancy rate per
pregnancy and miscarriage rate per pregnancy, and there was no stat-
istical difference between the two interventions.
Summary of narrative review evidence
Aromatase catalyses the conversion of androgens to oestrogens,
including in the ovary, and increase FSH secretion (Adashi, 1984),
stimulating ovarian follicle development and maturation. AIs prevent
this conversion. These agents were originally used to improve preg-
nancy rates and limit adverse effects (Casper, 2003; Healey et al.,
2003), especially with clomiphene resistance and failure (Imani et al.,
1999; Imani et al., 2002 January, Casper, 2003; Legro et al., 2007).
Letrozole has side-effects include gastrointestinal disturbances, hot
flushes, headache and back pain (Holzer et al., 2006; Legro et al.,
2014a,b) and concerns have been raised in an abstract on potential
teratogenic effects (Biljan et al., 2005), which are as yet unconfirmed in
peer-reviewed publications, yet this has sparked a series of warnings
to avoid use of AI in infertility. Multiple subsequent case series
(Tulandi et al., 2006; Forman et al., 2007; Dehbashi et al., 2009;
Sharma et al., 2014; Tatsumi et al., 2017), multi-centre RCTs (Legro
et al., 2014a,b; Diamond et al., 2015) and a recent systematic review
and meta-analysis (Wang et al., 2017), all failed to note an increased
congenital anomaly rate, with prevalence of anomalies with letrozole
or clomiphene under 5% (the expected anomaly rate in this population
is 5–8%) (Davies et al., 2012). Whilst use of letrozole is evidence-
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based, patient explanation and consent is appropriate as letrozole
therapy for infertility is off label.
Justification
Women with PCOS are significantly more likely both to ovulate and to
have a live birth after use of letrozole compared to clomiphene, the pre-
vious first line agent. The likelihood of live birth is increased 40–60%
with letrozole compared to clomiphene. Similarly, failure to ovulate
(letrozole resistance) is lower with letrozole versus clomiphene.
Multiple pregnancy rates appear lower with letrozole than clomiphene.
Hot flushes, generally the least desired side effect of any anti-oestrogen,
are less common with letrozole than clomiphene, but still present, while
fatigue and dizziness are more common with letrozole. The balance of
benefits in terms of improved live births with letrozole and less hot
flushes was considered to currently outweigh the adverse effects of rela-
tively increased fatigue and dizziness, multiple pregnancy, and uncon-
firmed concerns about higher congenital anomalies.
Clomiphene citrate and/or metformin
Clinical questions
In women with PCOS, is clomiphene citrate effective for improving fer-
tility outcomes?
In women with PCOS, is metformin effective for improving fertility
outcomes?
In women with PCOS and a BMI > 30–32 kg/m2, what is the effect-
iveness of metformin compared to clomiphene citrate for improving
fertility outcomes?
Clinical need for the questions
Clomiphene citrate is a selective oestrogen receptor modulator with
both oestrogenic and anti-oestrogenic properties (Shelly et al., 2008).
It was first approved for use in women with anovulation in 1967
(Pritts, 2010) and acts as an anti-oestrogen (Adashi, 1984).
Clomiphene citrate resistance and failure is well documented
(Palomba et al., 2009a) and a discrepancy is noted between good ovu-
lation rates and lower pregnancy rates due to the anti-oestrogenic
effects of clomiphene citrate on the endometrium and cervical mucus.
Rates of twin pregnancy and triplets with clomiphene citrate are 5–7%
and 0.3%, respectively, and ovarian hyperstimulation syndrome
(OHSS) is less than 1% (Kafy and Tulandi, 2007). The potential for bor-
derline increased risk of ovarian tumours with 12 cycles or more has
been noted (Rossing et al., 1994).
Insulin resistance is common in PCOS (Dunaif et al., 1989;
DeUgarte et al., 2005), driving ovarian androgen biosynthesis and
increased bioavailability of free androgens. Excess local ovarian andro-
gen production augmented by hyperinsulinaemia causes premature fol-
licular atresia and anovulation (Costello and Eden, 2003). This has led
to insulin-sensitizing drugs use in ovulation induction. Metformin has
been most widely studied in PCOS and has the most reassuring safety
profile (Palomba et al., 2009b). Efficacy has been controversial and
therapeutic regimens are not well standardized in clinical practice, with
variable doses in use (Hoeger et al., 2008).
Summary of systematic review evidence
Metformin versus placebo. One systematic review (Morley et al.,
2017) with up to 14 studies and one RCT (Kjotrod et al., 2011) were
identified to address this comparison. Metformin was better than pla-
cebo for live birth rate per participant, pregnancy rate per participant
and ovulation rate per participant. Pregnancy rate and ovulation rate
remained statistically significantly better than placebo when sub-
grouped by BMI (BMI < 30 kg/m2 and BMI > 30 or 32 kg/m2 sub-
groups); however live birth rate lost statistical significance when
subgrouped by BMI. There was no statistically significant difference
between metformin and placebo for miscarriage rate per pregnancy
(including when subgrouped). Gastrointestinal upsets were statistically
significantly lower with placebo than metformin (including when sub-
grouped). Multiple pregnancy and OHSS were not reported in the sys-
tematic review. It is important to note that the findings for live birth
rate and miscarriage rate are of low certainty due to serious risk of
bias and serious risk of imprecision in the body of evidence; and find-
ings for pregnancy rate, ovulation rate and adverse events are of mod-
erate certainty due to serious risk of bias. Risk of bias appraisals and
GRADE assessments have been adopted from previous versions of
this guideline (Balen et al., 2016).
In an RCT of 149 participants, with moderate certainty, there were
no statistically significant differences between metformin and placebo
for pregnancy rate per participant, multiple pregnancy rate per preg-
nancy or miscarriage rate per pregnancy. The majority of the trials
stopped metformin at diagnosis of pregnancy or at week 12. Note:
insufficient evidence of a differential effect of metformin on BMI.
Clomiphene citrate versus placebo. One high-quality systematic
review with low risk of bias found that clomiphene citrate was better
than placebo for pregnancy rate per participant and ovulation rate per
participant, however the evidence was of very low certainty due to
very serious risk of bias and imprecision (Brown and Farquhar, 2016).
Metformin versus clomiphene citrate. One systematic review (Morley
et al., 2017) with up to seven studies was identified to address this
comparison. There were no statistically significant differences between
metformin and clomiphene for live birth rate per pregnancy, multiple
pregnancy per pregnancy, miscarriage rate per pregnancy, pregnancy
rate or ovulation rate. When subgrouped by BMI, clomiphene citrate
was better than metformin for live birth rate, pregnancy rate and ovu-
lation rate in BMI > 30 kg/m2; and metformin was better than clomi-
phene citrate for pregnancy rate in BMI < 30 kg/m2. Adverse events
and OHSS were not reported in the systematic review. It is important
to note that the findings for live birth rate, multiple pregnancy rate and
pregnancy rate are of very low certainty due to very serious risk of
bias, serious risk of imprecision and for live birth rate, also serious risk
of inconsistency; findings for miscarriage rate and ovulation rate are of
low certainty due to serious risk of bias and serious risk of imprecision
in the body of evidence.
Metformin versus metformin + clomiphene citrate. One high-quality
systematic review with low risk of bias evaluating two RCTs with a
mean BMI ≥ 30 kg/m2 (Palomba et al., 2009c) and two RCTs [one
medium quality RCT with moderate risk of bias (Johnson et al., 2010)
and one low-quality RCT with high risk of bias (Karimzadeh and
Javedani, 2010)] were identified by the search. Metformin plus clomi-
phene citrate was better than metformin alone for ovulation rate,
pregnancy rate and live birth rate. There was no statistically significant
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difference between metformin plus clomiphene citrate and metformin
alone for miscarriage rate or adverse events.
Clomiphene citrate versus metformin + clomiphene citrate. One sys-
tematic review (Morley et al., 2017) with up to 21 studies, and one
RCT (Maged et al., 2015) were identified to address this comparison.
Metformin plus clomiphene citrate was statistically significantly better
than clomiphene citrate alone for pregnancy rate per participant and
ovulation rate per participant, including when subgrouped by BMI
(BMI < 30 kg/m2 and BMI > 30 kg/m2 subgroups). Adverse events
were statistically significantly fewer with clomiphene citrate alone than
with metformin plus clomiphene citrate. There was no statistically sig-
nificant difference between metformin plus clomiphene citrate and
clomiphene citrate alone for live birth rate per pregnancy, multiple
pregnancy rate per pregnancy or miscarriage rate per pregnancy.
OHSS was not reported in the systematic review. It is important to
note that the findings for live birth rate, multiple pregnancy and miscar-
riage rate are of low certainty due to serious risk of bias and serious
risk of imprecision in the body of evidence; and findings for pregnancy
rate, ovulation rate and adverse events are of moderate certainty due
to serious risk of bias. The additional RCT (Maged et al., 2015) was
insufficient evidence to supplement the findings of Morley et al. (2017).
Clomiphene citrate versus AI (letrozole). Thirteen RCTs (level II)
compared letrozole with clomiphene citrate. Seven of these RCTs had
a high risk of bias (Atay et al., 2006; Zeinalzadeh et al., 2010; Sheikh-El-
Arab Elsedeek and Elmaghraby, 2011; Banerjee Ray et al., 2012; Kar,
2012; Nazik and Kumtepe, 2012; Selim and Borg, 2012), two had a
moderate risk of bias (Begum et al., 2009; Dehbashi et al., 2009) and
four had a low risk of bias (Bayar et al., 2006; Badawy et al., 2009; Roy
et al., 2012; Legro et al., 2014a,b). Upon meta-analysis, we found that
letrozole was better than clomiphene citrate for ovulation rate per
patient (Atay et al., 2006; Begum et al., 2009; Dehbashi et al., 2009;
Sheikh-El-Arab Elsedeek and Elmaghraby, 2011; Banerjee Ray et al.,
2012; Nazik and Kumtepe, 2012; Roy et al., 2012; Legro et al., 2014a,
b); pregnancy rate per patient (Atay et al., 2006; Bayar et al., 2006;
Badawy et al., 2009; Begum et al., 2009; Dehbashi et al., 2009;
Zeinalzadeh et al., 2010; Sheikh-El-Arab Elsedeek and Elmaghraby,
2011; Banerjee Ray et al., 2012; Kar, 2012; Nazik and Kumtepe, 2012;
Roy et al., 2012; Selim and Borg, 2012; Legro et al., 2014a,b); and per
cycle (Nazik and Kumtepe, 2012; Roy et al., 2012; Selim and Borg,
2012); and live birth rate per patient (Bayar et al., 2006; Dehbashi
et al., 2009; Banerjee Ray et al., 2012; Roy et al., 2012; Legro et al.,
2014a,b). There was no difference between letrozole and clomiphene
citrate for ovulation rate per cycle (Bayar et al., 2006; Badawy et al.,
2009; Nazik and Kumtepe, 2012; Roy et al., 2012; Selim and Borg,
2012); multiple pregnancy rate per patient (Atay et al., 2006; Badawy
et al., 2009; Dehbashi et al., 2009; Zeinalzadeh et al., 2010; Kar, 2012;
Nazik and Kumtepe, 2012; Roy et al., 2012; Legro et al., 2014a,b) and
miscarriage rate per patient (Bayar et al., 2006; Badawy et al., 2009;
Begum et al., 2009; Dehbashi et al., 2009; Banerjee Ray et al., 2012;
Kar, 2012; Nazik and Kumtepe, 2012; Roy et al., 2012; Legro et al.,
2014a,b). When subgroup analysis was conducted for studies that
included women with PCOS who were therapy naïve, there was no
difference between the two interventions for any outcome, though we
note that for pregnancy rate per patient the OR 1.68 [95% CI 0.96,
2.94] had an I2 of 0% and a P value of 0.07.
Clomiphene citrate versus gonadotrophin (FSH). Two RCTs were
identified by the search to address this comparison. One RCT with
low-quality and high risk of bias (Lopez et al., 2004) compared recom-
binant FSH with clomiphene citrate in women with PCOS who were
therapy naïve and found that there was no difference between the two
interventions for all fertility outcomes. The second was a multi-centre
RCT with moderate risk of bias (Homburg et al., 2012) comparing
clomiphene citrate with low-dose gonadotrophins, as the first line
therapy for ovulation induction in anovulatory women with PCOS
who were therapy naïve. They reported with per protocol analysis
that the clinical pregnancy rate was significantly higher in the gonado-
trophin treated group. Furthermore, the chance of pregnancy was
almost double in the first treatment cycle when compared to clomi-
phene citrate. Brown and Farquhar (2016) meta-analysed these same
two RCTs combining data for live birth rate and ongoing pregnancy
rate and found that gonadotrophins were better than clomiphene cit-
rate (OR 0.64 [0.41, 0.98] P = 0.041, I2=0%). Meta-analysis of the two
studies for clinical pregnancy rate found that clomiphene citrate was
better than gonadotrophins (OR 0.61 [0.40, 0.93] P = 0.021, I2=0%).
It is important to be cautious of these results (using per protocol event
rates), as the number of participants randomized has been used as the
denominator when the denominator should have been the number of
participants per protocol.
Clomiphene citrate versus clomiphene citrate + gonadotrophin
(FSH). Two RCTs were identified to address this comparison, how-
ever there was insufficient evidence to determine whether one inter-
vention was better than the other (Mukherjee et al., 2010; Abu
Hashim et al., 2012).
Justification
Clomiphene citrate therapy requires specialist care. Costs to the
patient of monitoring (tests and specialist visits) and accessibility to
specialist care may present barriers, however increased costs will be
offset by reduced multiple pregnancies. Metformin is low cost, access-
ible and can be used alone and/or in combination with clomiphene cit-
rate, given efficacy on systematic review. Usual doses of metformin
range from 1500 mg (most commonly) to 1700 mg per day for non-
fertility studies. A change in usual care may result as clinicians may now
be more likely to prescribe metformin. Metformin may be associated
with mild gastrointestinal related adverse events (see Chapter 4 of full
guideline document). Whilst use is evidence-based, patient explan-




In women with PCOS, are gonadotrophins effective for improving fer-
tility outcomes?
Clinical need for the question
Gonadotrophin therapy is used clinically in women with anovulatory
PCOS who have been treated with other first line ovulation induction
agents if they have failed to ovulate or if the responses reduce chances
of conception (e.g. persistent hypersecretion of LH, or an anti-
oestrogenic endometrial effects). To prevent overstimulation and
10 Costello et al.
multiple pregnancy, the traditional standard step-up regimens
(Lunenfeld and Insler, 1974) were replaced by either low-dose step-up
regimens (Hamilton-Fairley et al., 1991; White et al., 1996) or step-
down regimens (van Santbrink et al., 1995) with gonadotrophins used
alone and different gonadotrophin preparations appearing to work
equally well (Nugent et al., 2000). It can be difficult to predict stimula-
tion responses in PCOS and to achieve a single dominant follicle to
reduce multiple pregnancy and OHSS, and careful monitoring of fol-
licular development by ultrasound is required with triggers only used
with two or less follicles over 14 mm. The efficacy, safety and role of
gonadotrophins compared to other alternatives, including single or
combined oral ovulation induction agents or laparoscopic surgery,
remains unclear.
Summary of systematic review evidence
Gonadotrophin (FSH) versus clomiphene citrate. Two RCTs were
identified by the search to address this comparison. One RCT with
low quality and a high risk of bias (Lopez et al., 2004) compared
recombinant FSH with clomiphene citrate in women with PCOS who
were therapy naïve and found that there was no difference between
the two interventions for all fertility outcomes. The second was a
multi-centre RCT with moderate risk of bias (Homburg et al., 2012)
comparing clomiphene citrate with low-dose gonadotrophins as the
first line therapy for ovulation induction in anovulatory women with
PCOS who were therapy naïve. They reported with per protocol ana-
lysis that the clinical pregnancy rate was significantly higher in the
gonadotrophin treated group. Furthermore, the chance of pregnancy
was almost double in the first treatment cycle when compared to
clomiphene citrate. Brown and Farquhar (2016) meta-analysed these
same two RCTs combining data for live birth rate and ongoing preg-
nancy rate and found that gonadotrophins were better than clomi-
phene citrate (OR 0.64 [0.41, 0.98] P = 0.041, I2=0%). Meta-analysis
of the two studies for clinical pregnancy rate found that clomiphene
citrate was better than gonadotrophins (OR 0.61 [0.40, 0.93] P =
0.021, I2=0%). It is important to be cautious of these results (using per
protocol event rates), as the number of participants randomized has
been used as the denominator when the denominator should have
been the number of participants per protocol.
Gonadotrophins versus clomiphene citrate + metformin. Two RCTs
compared FSH with clomiphene citrate plus metformin (Abu Hashim,
et al. 2011a,b, Begum et al., 2013). The RCTs found that FSH was bet-
ter than clomiphene citrate plus metformin for ovulation rate per par-
ticipant and pregnancy rate per participant. There was no statistical
difference between the two interventions for live birth rate per partici-
pant, multiple pregnancy rate per pregnancy, OHSS, miscarriage rate
per pregnancy or gastrointestinal side-effects or adverse events. A sys-
tematic review by Abu Hashim et al. (2015) conducted a meta-analysis
including RCTs comparing gonadotrophins versus clomiphene citrate
combined with metformin in clomiphene resistant PCOS women that
do not meet our PICO (P—patient, problem or population; I—inter-
vention; C—comparison, control or comparator; O—outcome), how-
ever some sensitivity analysis was conducted with the two RCTs listed
below. A sensitivity analysis for ovulation rate in 263 patients demon-
strated that gonadotrophins are better for ovulation rate (OR 0.13;
95% CI 0.07–0.25; P < 0.00001, I2 = 7%); but there was no statistically
significant difference between the two interventions for multiple preg-
nancy rate (n = 263, OR 0.33; 95% CI 0.06–1.68; P = 0.18, heterogen-
eity not reported). This meta-analysis, which the GDG considered to
be clinically relevant, demonstrated a significantly higher ovulation, clin-
ical pregnancy and ongoing pregnancy/live birth rate with gonadotro-
phins compared to clomiphene citrate plus metformin in clomiphene
resistant PCOS women.
Gonadotrophins versus gonadotrophins + metformin. One RCT with
moderate risk of bias found that FSH plus metformin was better than
FSH alone for live birth rate per participant, ovulation rate per partici-
pant and pregnancy rate per participant (Begum et al., 2013). There
was no statistical difference between the two interventions for mul-
tiple pregnancy rate per pregnancy, miscarriage rate per pregnancy or
adverse events.
A Cochrane review evaluating the use of metformin as an adjunct to
gonadotrophin ovulation induction in PCOS (Bordewijk et al., 2017)
was identified by the search, however it included studies that did not
meet the selection criteria for this question. The GDG considered the
meta-analyses in the Cochrane review as clinically relevant. The meta-
analysis demonstrated a statistically significantly higher ongoing preg-
nancy, clinical pregnancy and live birth rate with no statistically signifi-
cant difference in multiple pregnancy, miscarriage or OHSS rates when
metformin is combined with gonadotrophins in clomiphene citrate-
resistant PCOS women.
Gonadotrophins versus laparoscopic ovarian surgery. One high-
quality systematic review of RCTs (Level I) with low risk of bias com-
pared laparoscopic ovarian surgery to gonadotrophins and found that
there was no difference between the interventions for live birth rate
per patient and pregnancy rate per patient, ovulation rate per patient
and miscarriage rate per pregnancy, but laparoscopic ovarian surgery
had a lower multiple pregnancy rate (OR 0.13 [0.03–0.59] I2 = 0%,
four studies, 303 participants) (Farquhar et al., 2012) compared to
gondaotrophins.
Gonadotrophins versus gonadotrophins + clomiphene citrate. One
RCT (Ghanem et al., 2013) with moderate risk of bias found that FSH
plus clomiphene citrate was better than FSH alone for ovulation rate
per woman randomized and per protocol, total FSH dose used per
woman randomized and per protocol, and duration of stimulation per
woman randomized and per protocol. There was no statistical differ-
ence between the two interventions for pregnancy rate and live birth
rate per woman randomized and per protocol.
Justification
Gonadotrophin therapy is suitable for improving infertility in women
with PCOS in specialist care, with close monitoring. Gonadotrophin
therapy provides better per cycle and cumulative pregnancy and live
birth rates compared with the use of oral anti-oestrogens and/or no
therapy in anovulatory women with PCOS; and there is no evidence of
teratogenicity. It is important to note that gonadotrophin therapy
requires daily injections and the need for intensive monitoring with
ultrasound; with a risk of multiple pregnancy, OHSS and increased
cost of medication compared with oral agents.
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Anti-obesity agents
Clinical question
In women with PCOS, are anti-obesity pharmacological agents effect-
ive for improving fertility outcomes?
Clinical need for the question
A 2017-systematic review and meta-analysis (Domecq et al., 2013)
found that lifestyle interventions benefitted weight loss and natural
pregnancy rate, with limited evidence for live birth rate or birthweight,
yet natural birth rate did increase (Kiddy et al., 1992; Clark et al.,
1995). Hence, the impact of non-pharmacological lifestyle interven-
tions on live birth rates remains controversial. Engagement and adher-
ence in lifestyle interventions are challenging. There is a need to assess
other weight loss methods, such as pharmacological agents com-
menced in the pre-conception period, with some evidence they can
induce weight loss and improve fertility outcomes in PCOS.
Summary of systematic review evidence
We did not identify any evidence in women with PCOS to answer the
question and therefore the literature has been reviewed narratively.
Summary of narrative evidence
A randomized trial (that did not meet the inclusion criteria for this sys-
tematic review due to a change in interventions and combination of
treatments) evaluated pre-conception treatment in women with
PCOS with: lifestyle weight loss intervention incorporating caloric
restriction, increased physical activity and pharmacological agent (ini-
tially sibutramine, and then orlistat); oral contraceptive pill; combined
lifestyle and contraceptive pill on fertility outcomes (Legro et al.,
2015). The trial randomized 149 women, and was stopped prema-
turely due to supposed futility with a low likelihood of showing a clinic-
ally meaningful difference. Given the small sample size in a three-arm
trial, with no control group, no meaningful conclusions can be inferred.
Within the lifestyle arm, including anti-obesity agents, there was a sig-
nificant reduction in weight from baseline (−6.2Kg, 95% CI −07.1 to
−5.3), and compared to the women on a combined oral contraception
pill pre-conception, those on lifestyle with anti-obesity agents showed
no differences in pregnancy outcomes. Evidence for these agents in
other relevant population groups is lacking.
Justification
With inadequate evidence in both PCOS and infertility generally, the
risk/benefit ratio is currently too uncertain to advocate anti-obesity
pharmacological agents as a fertility treatment and it was deemed that
it should remain an experimental treatment for this indication.
Laparoscopic ovarian surgery
Clinical question
In women with PCOS, is ovarian surgery effective for improving fertility
outcomes?
Clinical need for the question
Observations that women with PCOS resumed regular ovulation fol-
lowing ovarian biopsies led to the development of surgical wedge
resection via laparotomy (Stein, 1964). Observational data looked
promising, but surgery was surpassed by ovulation induction agents
until less invasive laparoscopic surgery was developed (Gjønnæss,
1984), with potential for fewer adhesions and lower cost. Minor meth-
odological variations are reported (electrocautery, laser vaporization,
multiple ovarian biopsies and others), all seemingly with effects on the
endocrine profile. OHSS and multiple pregnancy risks are lower than
with other options, but other risks potentially are higher, and clarifica-
tion of the role of laparoscopic ovarian surgery, particularly in compari-
son to other treatments, is needed in infertile women with PCOS.
Summary of systematic review evidence
Laparoscopic ovarian surgery versus metformin. Two medium quality
RCTs (Level II) (published across three papers) with a moderate risk
of bias compared laparoscopic ovarian surgery to metformin and
found that there was insufficient evidence to make a recommendation
about laparoscopic ovarian surgery compared to metformin for live
birth rate per patient, ovulation rate per cycle, pregnancy rate per
cycle, pregnancy rate per patient, multiple pregnancies, miscarriage
rate per pregnancy, adverse effects and quality of life (QOL; Palomba
et al., 2004, 2005; Hamed et al., 2010) largely because the evidence
was conflicting. One RCT reported that laparoscopic ovarian surgery
was better than metformin for ovulation (OR 2.05; [1.4–2.9] P =
0.001) and pregnancy rate (per cycle: OR 2.19 [1.03–4.63] P = 0.03;
per patient: OR 2.47 [1.05–5.81] P = 0.03) (Hamed et al., 2010) and
the other study reported that metformin was better than laparoscopic
ovarian surgery for live birth rate (metformin: 82.1%, LOS: 64.5%, P <
0.05), pregnancy rate per cycle (metformin: 18.6%, LOS: 13.4%, P <
0.05), and miscarriage rate (metformin: 15.4%, LOS:29.0%, P < 0.05)
(Palomba et al., 2004, 2005). Both medium quality single centre studies
had a small sample size and moderate risk of bias and therefore need
to be interpreted with caution.
Laparoscopic ovarian surgery versus clomiphene citrate. Two high-
quality RCTs (Level II) with a low risk of bias compared laparoscopic
ovarian surgery to clomiphene citrate (Amer et al., 2009, Abu Hashim,
et al. 2011a,b) and found that there was no difference between laparo-
scopic ovarian surgery and clomiphene citrate for live birth rate per
patient and pregnancy rate per patient, ovulation rate per patient and
miscarriage rate per pregnancy (Amer et al., 2009, Abu Hashim, et al.
2011a). There was insufficient evidence to support or refute the use of
laparoscopic ovarian surgery over clomiphene citrate for multiple
pregnancies (Amer et al., 2009, Abu Hashim, et al. 2011a,b).
Laparoscopic ovarian surgery versus clomiphene citrate + metfor-
min. Three low to moderate-quality RCTs with low to moderate risk
of bias compared laparoscopic ovarian surgery to clomiphene citrate
plus metformin [all three studies reported in Farquhar 2012 systematic
review (Farquhar et al., 2012)]. Meta-analyses found that clomiphene
citrate plus metformin was better than laparoscopic ovarian surgery
for live birth rate, but there was no difference for pregnancy rate per
patient, multiple pregnancy rate, or miscarriage rate per pregnancy
(Farquhar et al., 2012). There was insufficient evidence to support or
refute the use of laparoscopic ovarian surgery over clomiphene citrate
plus metformin for ovulation rate per patient, and OHSS (Farquhar
et al., 2012).
Laparoscopic ovarian surgery versus AIs. Three RCTs with low risk of
bias (Abu Hashim et al., 2010a, Abdellah, 2011; Ibrahim et al., 2017)
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compared letrozole to laparoscopic ovarian surgery and found that
there was insufficient evidence of a difference between letrozole and
laparoscopic ovarian surgery. One of the RCTs in 147 women with
clomiphene citrate resistance found that letrozole was better than lap-
aroscopic ovarian surgery for ovulation rate per cycle (Abdellah,
2011), however the evidence is of low certainty. The systematic
review by Farquhar et al. (2012) combined these studies in meta-
analysis for pregnancy rate per patient, multiple pregnancy rate per
pregnancy and miscarriage rate per pregnancy and there was no statis-
tical difference between the two interventions.
Laparoscopic ovarian surgery versus aromatase inhibitors + metfor-
min. One low-quality RCT with moderate risk of bias compared lap-
aroscopic ovarian surgery with letrozole plus metformin and found
that there was insufficient evidence of a difference between the two
interventions for ovulation, pregnancy and miscarriage rate per preg-
nancy (Abd Elgafor, 2013).
Laparoscopic ovarian surgery versus gonadotrophins. One high-
quality systematic review of RCTs (Level I) with low risk of bias com-
pared laparoscopic ovarian surgery to gonadotrophins and found that
there was no difference between the interventions for live birth rate
per patient and pregnancy rate per patient, ovulation rate per patient
and miscarriage rate per pregnancy, but laparoscopic ovarian surgery
was better than gonadotrophins for multiple pregnancy rate (OR 0.13
[0.03–0.59] I2 = 0%, four studies, 303 participants) (Farquhar et al.,
2012).
Summary of narrative review evidence
Observational data was sourced to evaluate long-term impacts. A
15–25-year follow-up of nearly 150 women after ovarian wedge resec-
tion shows that regular menstrual patterns lasting up to 25 years after
surgery were restored in 88% of patients with a cumulative preg-
nancy/live birth rate of 78% (Lunde et al., 2001). This was considered
along with the RCT data.
Justification
Laparoscopic ovarian surgery is an intervention that can lead to a
singleton birth in women with PCOS. There is no convincing evidence
of inferiority over other common ovulation induction agents, there is
no need for monitoring (because of mono-ovulation) and only a back-
ground risk of multiple pregnancy. However, it is important to note
that laparoscopic ovarian surgery is an invasive surgical intervention;
there is a small risk of reduced ovarian reserve or loss of ovarian func-
tion, and adhesion formation should be considered. Issues covered in
the CPP should be carefully considered.
Bariatric surgery
Clinical question
In women with PCOS, what is the effectiveness of lifestyle interven-
tions compared to bariatric surgery for improving fertility and adverse
outcomes?
Clinical need for the question
Obesity is increasing in prevalence throughout the world, as is morbid
obesity (BMI≥ 40 kg/m2) (Sturm and Hattori, 2013). Women with
PCOS have higher rates of weight gain and of obesity, adversely affect-
ing fertility. Weight loss improves outcomes, as previously outlined. In
severe obesity, lifestyle interventions have limited efficacy. Substantial
efficacy of bariatric surgery on weight loss has been demonstrated in
severely obese women. Potential benefits need to be balanced with
the delay in infertility treatment and pregnancy for surgery and stabil-
ization of weight, the risks of bariatric surgery and the potential risks of
pregnancy after bariatric surgery. Controversy persists around efficacy
for fertility and pregnancy outcomes, optimal timing, adverse effects
and comparative efficacy with other treatments, as well as on adverse
effects on subsequent pregnancies.
Summary of systematic review evidence
We did not identify any evidence in women with PCOS to answer the
question and therefore the literature has been reviewed narratively.
Summary of narrative review evidence
UK clinical guidelines for obesity management in the general popula-
tion (Scottish Intercollegiate Guidelines Network, 2010) recommend
considering bariatric surgery with a BMI ≥35 kg/m2 with one or more
severe complications expected to improve with weight loss and failure
of structured lifestyle intervention (Scottish Intercollegiate Guidelines
Network, 2010). Obesity surgery can be considered after non-surgical
treatment has failed with a BMI ≥40 kg/m2 and obesity surgery can be
first line treatment with a BMI ≥50 kg/m2 (National Institute for
Health and Clinical Excellence, 2006). Other guidelines recommend
lower barriers to surgery (Jensen et al., 2014). For type of surgery, ver-
tical sleeve gastrectomy has overtaken the roux-en-Y gastric bypass
and gastric band surgery as the most commonly performed bariatric
surgery, with lower operative morbidity (Lager et al., 2017).
Adjustable gastric banding, once the choice for women planning preg-
nancy, is now less common given complications and overall lower
long-term weight loss (Lager et al., 2017).
High-quality RCTs of bariatric surgery versus medical management
in type 2 diabetes mellitus show persistent benefits and superiority of
weight loss and bariatric surgery in curing or ameliorating diabetes
(Mingrone et al., 2012; Schauer et al., 2017). Yet these studies are
absent in PCOS for fertility and pregnancy outcomes, with current
PCOS studies poorly designed (Shah and Ginsburg, 2010), and with
failure to report key perinatal outcomes to inform risk to benefit ratio.
In PCOS, the balance between delaying infertility treatment and preg-
nancy whilst undertaking bariatric surgery and attaining stable post-
operative weight, is also unclear (Mutsaerts et al., 2016), as is the opti-
mal type of bariatric surgery.
Bariatric surgery can cause malabsorption and psychological issues
including disordered eating (Månsson et al., 2008) and may adversely
affect maternal and neonatal health. Adequate intake and absorption
of iron, folate, iodine and other nutrients are of concern. While sup-
plement use is widely recommended following bariatric surgery, espe-
cially for pregnant women, there are reports of poor compliance
(Nilsen et al., 2006) and challenges tolerating fortified foods such as
bread. National registries (surgery, pregnancy, infants) show that
obese women who undergo bariatric surgery and conceive, compared
to similarly obese controls, had more small for gestational age babies,
shorter gestations, and a trend towards increased neonatal mortality
(Johansson et al., 2015), with similar findings in retrospective studies
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(Gonzalez et al., 2015). Benefits have included less gestational diabetes
mellitis and large for gestational age babies.
Justification
Bariatric surgery improves weight loss and can improve comorbidities
associated with PCOS. However, evidence in relation to fertility and
pregnancy outcomes is limited, with some concerns about potential
perinatal adverse effects of bariatric surgery. Overall, the indications,
role and comparative effectiveness with other fertility therapies, ideal
timing, optimal type of surgery, adverse effects and risk to benefit ratio
in PCOS are still to be resolved. Given the concerns about the poten-
tial perinatal adverse effects of bariatric surgery and the remaining con-
troversies, no recommendation can be made at this time about the




In women with PCOS, is stimulated IVF/ICSI effective for improving
fertility outcomes?
Clinical need for the question
Ovulation induction therapies are first and second line in infertility
management in women with PCOS, anovulation and no other fertility
factors. Yet resistance to and failure of ovulation induction therapies
and inability to overcome other concomitant causes of infertility means
that ART therapies, including IVF and ICSI, used in male factor infertil-
ity, have a role in PCOS. IVF has risks and limitations, yet also offers
the opportunity for pregnancy and live birth. Challenges exist across
the diversity of protocols available for IVF and concerns in PCOS
including OHSS, high oestradiol levels, accelerated endometrial matur-
ation and optimally the use of ‘freeze all’ interventions. The clinical
practice questions here include indications, timing and comparative
efficacy with other treatments, yet RCTs in this area are very limited in
women with anovulatory PCOS.
Summary of systematic review evidence
We did not identify any evidence in women with PCOS to answer the
question and therefore the literature has been reviewed narratively.
Summary of narrative review evidence
There are no RCTs identified by the guideline development team,
comparing stimulated IVF ± ICSI therapy with ovulation induction in
women diagnosed with PCOS. The role of IVF in PCOS was explored
by the WHO guidance group, and the review and recommendations
were considered here by the GDG, in making their recommendations
(Balen et al., 2016). Factors that influenced considerations here include
access, cost and risks. The patient and societal benefits of ovulation
induction compared with IVF treatments in anovulatory PCOS women
require RCTs and systematic analysis. Outcomes such as time to con-
ception, cost of therapy, QOL, OHSS risk, multiple pregnancy, miscar-
riage and live birth rates should be investigated.
Justification
The GDG deemed IVF should be considered after failed ovulation
induction treatment with high pregnancy rates per cycle, especially in
younger women. Given the risks and the high costs that can be pro-
hibitive for many patients, IVF should be considered a third-line med-
ical therapy. It was noted that conception and delivery are highly
valued by health professionals and women with PCOS and even when
cost and risks are increased, many may elect to undertake IVF. Health
professionals must weigh benefits and risk when advising PCOS
patients to enable an informed decision.
GnRH protocol
Clinical question
In women with PCOS undergoing IVF/ICSI treatment, is the GnRH
antagonist protocol or GnRH agonist long protocol the most effective
for improving fertility outcomes?
Clinical need for the question
Women with PCOS are particularly vulnerable to OHSS with IVF ±
ICSI treatment, prompting caution and leading to exploration of differ-
ent protocols, including with GnRH and other options such as IVM
(Walls et al., 2015a). One of the proposed methods to reduce the risk
of OHSS is to use a GnRH antagonist (as opposed to an agonist) (Al-
Inany et al., 2007; Mancini et al., 2011; Lin et al., 2014; American
Society for Reproductive Medicine, 2016). There is acknowledged
complexity in interpreting outcomes from IVF treatments in PCOS,
with variable protocols and endpoint reporting, requiring close evalu-
ation of the literature. One of the proposed methods to reduce the
risk of OHSS is to use a GnRH antagonist (as opposed to an agonist)
to suppress pituitary LH secretion.
Summary of systematic review evidence
In the eight included studies of low (Hwang et al., 2004; Kurzawa et al.,
2008; Tehraninejad et al., 2010), moderate (Bahceci et al., 2005;
Lainas et al., 2007, 2010; Mokhtar et al., 2015), and high risk of bias
(Haydardedeoglu et al., 2012) comparing a GnRH antagonist protocol
with a long GnRH agonist protocol, there were statistically significant
differences in the amount of gonadotrophin required (five studies in
favour of the antagonist protocol) (Hwang et al., 2004; Kurzawa et al.,
2008; Lainas et al., 2010; Tehraninejad et al., 2010; Haydardedeoglu
et al., 2012), in the duration of gonadotrophin use (six studies in favour
of the antagonist protocol) (Bahceci et al., 2005; Lainas et al., 2007,
2010; Kurzawa et al., 2008; Tehraninejad et al., 2010; Haydardedeoglu
et al., 2012), in OHSS rates (two studies in favour of the antagonist
protocol) (Lainas et al., 2007; Tehraninejad et al., 2010). No statistic-
ally significant differences were found between groups for clinical preg-
nancy rates, miscarriage rates, number of oocytes collected,
cancellation rates, and multiple pregnancy rates.
A systematic review and meta-analysis comparing the GnRH antag-
onist protocol versus GnRH agonist long protocol in women with
PCOS undergoing an IVF ± ICSI cycle (Pundir et al., 2012) was also
identified by the search, however it included studies that did not meet
the selection criteria for this question. The GDG considered this
meta-analyses as clinically relevant. The meta-analysis demonstrated a
statistically significantly reduction in the total dose of gonadotrophins,
duration of gonadotrophin stimulation and rate of moderate to severe
OHSS with the GnRH antagonist protocol, with no statistically signifi-
cant difference in clinical pregnancy, miscarriage or number of eggs
collected.
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Justification
The duration of stimulation with a GnRH antagonist approach is
around 1 day shorter than the standard ‘long-down regulation’
approach with a GnRH agonist. The rate of OHSS appears less with a
GnRH antagonist approach in comparison to the standard ‘long-down
regulation’ approach with a GnRH agonist. The effect size is difficult to
quantify, as all most of these studies used a high dose hCG trigger in
both arms, whereas this may not reflect clinical practice. There does
not appear to be an increase in undesirable side-effects with an
antagonist down-regulation approach. The choice to trigger final




In women with PCOS undergoing GnRH antagonist IVF/ICSI treat-
ment, is the use of hCG trigger or GnRH agonist trigger the most
effective for improving fertility outcomes?
Figure 2 PCOS consumer information graphic—PCOS, fertility and pregnancy. PCOS: polycystic ovary syndrome.
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Clinical need for the question
One of the prominent causes of OHSS is the occurrence in women
with PCOS undergoing ovarian hyperstimulation for IVF, particularly
where hCG is used to trigger ovulation. Early in 1990, an alternative to
exogenous hCG triggering emerged with GnRH-agonist use, providing
an additional ovulatory option for IVF. A single bolus of GnRH-agonist
administration during late follicular development in women with PCOS
treated with gonadotrophins results in a surge of endogenous FSH and
LH for final oocyte maturation and fertilization. OHSS appears
reduced yet lower pregnancy rates with GnRH-agonist triggers are
observed and may vary when transferring fresh versus frozen-thawed
embryos in cycles from the same cohort, suggesting that the pregnancy
rate is dependent of endometrial quality. An alternative option there-
fore in women with PCOS at high risk of OHSS is to freeze oocytes or
embryos after GnRH agonist triggering and transfer the embryos in
subsequent cycles. The choice to trigger final oocyte maturation with
GnRH-agonist, instead of hCG, and to transfer frozen embryos
requires clarification.
Summary of systematic review evidence
We did not identify any evidence in women with PCOS to answer the
question and therefore the literature has been reviewed narratively.
Summary of narrative review evidence
This question was addressed in a Cochrane review in 2014 (Youssef
et al., 2014). In 17 RCTs (n = 1847), in fresh autologous cycles,
GnRH-agonists were associated with a lower live birth rate than hCG
(OR 0.47, 95% CI 0.31–0.70; five RCTs, 532 women, I2 = 56%,
moderate-quality evidence), yet there was also a lower incidence of
mild, moderate or severe OHSS than with hCG (OR 0.15, 95% CI
0.05–0.47; 8 RCTs, 989 women, I2 = 42%, moderate-quality evi-
dence). In fresh autologous cycles, GnRH-agonists were associated
with a lower ongoing pregnancy rate than hCG (OR 0.70, 95% CI
0.54–0.91; 11 studies, 1198 women, I2 = 59%, low-quality evidence)
and a higher early miscarriage rate (OR 1.74, 95% CI 1.10–2.75; 11
RCTs, 1198 women, I2 = 1%, moderate-quality evidence). However,
the effect was dependent on the type of luteal phase support pro-
vided. Multiple pregnancy rates were similar. The authors concluded
that final oocyte maturation triggering with GnRH-agonist instead of
hCG in fresh autologous GnRH-antagonist IVF ± ICSI cycles prevents
OHSS to the detriment of the live birth rate. In donor-recipient cycles,
use of GnRH agonists instead of hCG resulted in a lower incidence of
OHSS, with no evidence of a difference in live birth rate. GnRH agonist
as an oocyte maturation trigger could be useful for women who
choose to avoid fresh transfers, where donated oocytes are used or in
women who wish to freeze their eggs for later use.
Justification
The choice to trigger final oocyte maturation with GnRH-agonist
instead of hCG is important in prevention of OHSS as hCG alone
induces oocyte maturation but is associated with OHSS. GnRH-
agonist triggers are associated with lower pregnancy rates, primarily in
fresh embryo transfers, and data on cumulative pregnancy rates after
the use of all embryos frozen and replaced in thawed cycles needs spe-
cific focus in the future.
Figure 3 Screens shots of the PCOS App—AskPCOS.
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Choice of FSH
Clinical question
In women with PCOS undergoing (controlled) ovarian (hyper) stimula-
tion for IVF/ICSI, does the choice of FSH effect fertility outcomes?
Clinical need for the question
FSH can be purified from human urine (uFSH) or synthesized using
recombinant DNA techniques (rFSH). Urinary preparations have
impurities with LH activity known to stimulate androgen production in
theca cells and completing maturation of follicles. However, it is
known that less than 1% of follicular LH receptors needs to be occu-
pied in order to elicit maximal steroidogenesis and it is therefore pos-
sible that enough endogenous LH is present during controlled ovarian
stimulation to promote androgen synthesis and oocyte maturation
without the need for extra LH activity in FSH preparations. The per-
ceived clinical benefits of rFSH versus uFSH are the subject of ongoing
debate and both types of preparations remain commonly used.
Summary of systematic review evidence
One small study (80 participants) with moderate risk of bias compared
rFSH with hMG and found that rFSH was better for the duration of ovar-
ian stimulation required and the number of oocytes retrieved; whereas
hMG was better for the maximum serum estradiol level (Figen Turkcapar
et al., 2013). No statistically significant differences were found between
groups for the total dose of gonadotrophin used, OHSS rate, clinical preg-
nancy rate per cycle and take home baby rate per cycle.
Summary of narrative review evidence
Given the limited evidence in PCOS, additional information was sought
from rFSH and uFSH use in the general population. In a Cochrane system-
atic review and meta-analysis, 42 trials with a total of 9606 couples com-
pared rFSH against three different uFSH preparations (van Wely et al.,
2011). rFSH, irrespective of the down-regulation protocol, did not result
in a statistically significant different live birth rate or OHSS rate, concluding
that clinical choice of gonadotrophin should depend on availability, con-
venience and costs, and that further research on these comparisons is
unlikely to identify substantive differences in effectiveness or safety.
Justification
Only one small study in PCOS has been identified investigating uFSH
versus rFSH in PCOS during ovarian stimulation for IVF/ICSI (Figen
Turkcapar et al., 2013). This study shows similar results to a systematic
review and meta-analysis in the general IVF population, where exten-
sive research has concluded no significant difference in birth rate or
OHSS was detected and no further research in the general population
was recommended. Hence clinical choice of gonadotrophin should
depend on availability, convenience and costs.
Exogenous LH
Clinical question
In women with PCOS undergoing (controlled) ovarian (hyper) stimula-
tion for IVF/ICSI, is exogenous LH treatment during IVF±ICSI effective
for improving fertility outcome?
Clinical need for the question
Options have been explored to reduce OHSS risk in IVF/ICSI in PCOS.
The low-dose step-up protocol with exogenous FSH in securing single
(fewer) dominant follicle selection is an alternative method to avoid multi-
follicular development. During late follicular development, LH is essential
to achieve adequate ovarian steroidogenesis and develop the subsequent
capacity of the follicle to ovulate and luteinize. Increased LH secretion or
elevated LH/FSH ratio in PCOS may influence fertility, with inhibition of
oocyte maturation, deleterious effects on granulosa cell steroidogenesis
and endometrial receptivity and with potential increased early pregnancy
loss (Jacobs and Homburg, 1990; Tarlatzis et al., 1995; Willis et al., 1998).
The lack of clarity around the role of exogenous LH in the setting of IVF/
ICSI prompted this clinical question.
Summary of systematic review evidence
We did not identify any evidence in women with PCOS to answer the
question and therefore the literature has been reviewed narratively.
Summary of narrative review evidence
Obesity adversely impacts on ovulation and on responses to ovulation
induction in PCOS (Kiddy et al., 1990). In PCOS, granulosa cells
respond to LH at a relatively earlier follicular stage and are significantly
more responsive than for ovulatory women with PCOS or women
without PCOS (Willis et al., 1998). Granulosa cell differentiation may
be prematurely advanced. Controlled ovarian stimulation for multiple
follicular development in ART can be performed in a variety of ways to
increase efficacy and reduce risks. Systematic reviews and meta-
analysis have demonstrated that there is no significant difference
between different ovarian stimulation protocols (hMG, purified FSH,
rFSH) regarding the fertility outcomes. Therefore, clinical gonado-
trophin choice depends on availability, convenience, and cost. In stand-
ard IVF/ICSI protocols, the types of controlled ovarian stimulation
(FSH alone or addition of LH as a supplement) have little impact on
the fertility outcomes (van Wely et al., 2011; Schwarze et al., 2016).
Endogenous LH levels may fall too low in older women (>35 years)
during ovarian stimulation, especially with GnRH-antagonist use, and
LH supplementation has been proposed. However, a multi-centre
RCT of exogenous LH during the follicular phase showed no fertility
benefit outcomes in women over 35 years of age (Konig et al., 2013).
No current study investigates efficacy of exogenous LH supplement
for fertility outcomes in PCOS during IVF/ICSI. Careful monitoring of
follicular development during ovarian stimulation is critical.
Justification
There is no anticipated effect or benefit to add exogenous LH supple-
ment in women with PCOS undergoing ovarian stimulation for IVF
±ICSI. There is insufficient evidence to determine the benefits of using
or not using exogenous LH.
Adjunct metformin
Clinical question
In women with PCOS undergoing (controlled) ovarian (hyper) stimula-
tion for IVF±ICSI, is adjunct metformin effective for improving fertility
outcomes?
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Clinical need for the question
IVF±ICSI treatment in women with PCOS is usually recommended
either third-line (after failed ovulation induction) or in those with other
infertility factors such as tubal damage, severe endometriosis or male
factors (Baskind and Balen, 2016). IVF±ICSI treatment in PCOS poses
challenges, including OHSS (Costello et al., 2006). Metformin has been
studied to restore ovulation and enhance pregnancy rates in PCOS
(Huang et al., 2015) through a range of mechanisms (Kjotrod et al.,
2004, 2011; Lin and Coutifaris, 2007). These mechanisms provide a
physiological rationale for management of insulin resistance in IVF in
PCOS. It has also been suggested that metformin may reduce serum
estradiol levels during ovarian stimulation and it has also been
hypothesized that metformin may reduce the production of vascular
endothelial growth factor, both of which are important factors
involved in the pathophysiology of OHSS (Legro, 2016). Therefore, it
was deemed important to explore the effectiveness and safety of met-
formin as a co-treatment in achieving pregnancy or live birth and redu-
cing OHSS in IVF in PCOS.
Summary of systematic review evidence
Six RCTs of low (Kjotrod et al., 2004; Tang et al., 2006; Palomba et al.,
2011), moderate (Kjotrod et al., 2011) and high risk of bias (Fedorcsak
et al., 2003; Onalan et al., 2005) found that IVF with adjuvant metfor-
min was better for OHSS, clinical pregnancy rate, cancellation rate and
live birth rate. No statistically significant differences were found
between groups for the amount of gonadotrophins used, the duration
of ovarian stimulation, miscarriage rates, number of oocytes collected,
and multiple pregnancy rates.
Summary of narrative review evidence
A Cochrane review (Tso et al., 2014) was identified by the search, how-
ever it included studies that did not meet the selection criteria for this
question. The GDG considered the meta-analyses in the Cochrane
review as clinically relevant and noted that there was no evidence of a
difference with adjunct metformin for live birth rate, miscarriage rate,
number of oocytes collected, days of ovarian stimulation or cycle cancella-
tion rate; and clinical pregnancy rate was increased with adjuvant metfor-
min whilst OHSS was reduced. Mild, generally self-limiting side-effects,
were noted with adjunct metformin, as outlined in Chapter 4.
Justification
Women and health professionals would generally value an increased
clinical pregnancy rate (with no evidence of a difference in miscarriage
rate) and reduced OHSS (with its associated morbidity and rarely
mortality). Gastrointestinal side-effects were recognized, but noted as
mild and self-limiting, and may be minimized with a lower metformin
starting dose and extended release preparations. Metformin was
noted to be low cost and readily available, and while off label use was
generally allowed, an explanation is required for use.
IVM
Clinical question
In women with PCOS, is IVM effective for improving fertility
outcomes?
Clinical need for the question
Where IVF is indicated in PCOS, OHSS risks are increased with
gonadotrophin stimulation. IVM of oocytes limits or omits ovarian
stimulation prior to oocyte retrieval, with maturation of oocytes post
retrieval, avoiding OHSS risk (Walls et al., 2015a). The definition of an
IVM cycle requires clarification (De Vos et al., 2016), as cycles employ-
ing an hCG trigger injection are generally associated with asynchron-
ous oocyte maturation rates, poor embryo implantation rates and
lower pregnancy rates (De Vos et al., 2011; Reavey et al., 2016).
There are no RCTs of IVM versus ICSI or ovulation induction in
PCOS, however observational studies suggest that offspring from IVM
are not adversely affected (Roesner et al., 2017b). Given that IVM is
used in practice and has theoretical benefits, this question was
prioritized.
Summary of systematic review evidence
We did not identify any evidence in women with PCOS to answer the
question and therefore the literature has been reviewed narratively.
Summary of narrative review evidence
With an absence of relevant RCTs (Sauerbrun-Cutler et al., 2015),
retrospective studies suggest IVM is similarly successful for live birth
with frozen embryos generated with IVM as embryo transfers gener-
ated by standard IVF treatment (Walls et al., 2015a). However, preg-
nancy rates are reduced and miscarriage rates are higher if a fresh
embryo transfer is performed with IVM (Walls et al., 2015a). Embryo
development appears slower with a greater degree of embryo arrest
in IVM (Walls et al., 2015b; Roesner et al., 2017a).
Justification
The GDG deemed that key elements to consider with IVM included a
clear definition of the term IVM, use in clinical units with sufficient
expertize and the advantages of a reduced risk of OHSS. The group
considered the lack of evidence as important. It was considered that
IVM could be offered to achieve pregnancy and live birth rates that
may approach those of standard IVF ± ICSI treatment, where frozen
embryos are used. Given the lack of evidence, the group voted for a
conditional consensus recommendation that neither favoured this
option or other options (IVF), with strong research recommendations.
Discussion
The recommendations in the international evidence-based guidelines
were formulated after engagement with professional societies and
consumer organizations with multidisciplinary experts and women
with PCOS directly involved at all stages. AGREE II-compliant pro-
cesses were followed, with extensive evidence synthesis. The GRADE
framework was applied across evidence quality, feasibility, acceptabil-
ity, cost, implementation and ultimately recommendation strength.
The evidence and recommendations for ovulation induction in this
guideline are applicable to women with PCOS who have anovulatory
infertility and no other infertility factors. The discussion will be limited
to what recommendations are considered new as compared to previ-
ous guidelines.
Letrozole should now be considered the first line pharmacological
treatment for ovulation induction (EBRs, strong recommendation, low
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QOE although evidence was of moderate quality for the outcomes of
ovulation, pregnancy and live-birth rates) although one could use
clomiphene citrate alone (EBRs, conditional recommendation, very
low QOE) or metformin alone (EBRs, conditional recommendation,
moderate QOE). If using metformin alone for ovulation induction,
then one should inform the woman that there are more effective ovu-
lation induction agents.
Gonadotrophins could also be considered as first line ovulation
induction treatment, in the presence of ultrasound monitoring, and fol-
lowing counselling on cost and potential risk of multiple pregnancy
(EBR, conditional recommendation, low QOE). Gonadotrophins
should be used in preference to clomiphene citrate combined with
metformin therapy for ovulation induction in clomiphene citrate-
resistant women with PCOS to improve live birth rates (EBRs, strong
recommendation, moderate QOE). Gonadotrophins with the addition
of metformin could be used rather than gonadotrophins alone to
improve live birth rates in clomiphene citrate-resistant PCOS women
(EBRs, conditional recommendation, moderate QOE).
Both pharmacological anti-obesity agents and bariatric surgery
should be considered experimental ovulation induction therapies for
the purpose of improving fertility and having a baby, with risk to benefit
ratios currently too uncertain to advocate these as fertility therapies
(CCR, conditional recommendation against the options, QOE not
applicable).
In the absence of an absolute indication for IVF ± ICSI, women with
PCOS and anovulatory infertility could be offered IVF as third-line
therapy where first or second line ovulation induction therapies have
failed (CCR, conditional recommendation, QOE not applicable). In
terms of the controlled ovarian hyperstimulation for IVF ± ICSI, a
GnRH antagonist protocol is preferred to reduce the duration of
stimulation, total gonadotrophin dose and incidence of OHSS (EBR,
conditional recommendation, low QOE), uFSH or rFSH can be used
due to insufficient evidence to recommend specific FSH preparations
(CCR, conditional recommendation, QOE not applicable), and
exogenous recombinant LH treatment should not be routinely used in
combination with FSH therapy (CCR, conditional recommendation,
QOE not applicable). Adjunct metformin therapy could be used
before and/or during FSH ovarian stimulation for IVF ± ICSI therapy
with a GnRH-agonist protocol, to improve the clinical pregnancy rate
and reduce the risk of OHSS (EBR, conditional recommendation, low
QOE).
In units with sufficient expertize, IVM could be offered to achieve
pregnancy and live birth rates approaching those of standard IVF ±
ICSI treatment without the risk of OHSS for women with PCOS,
where an embryo is generated, then vitrified and thawed and trans-
ferred in a subsequent cycle (CCR, conditional recommendation for
either the IVM or standard IVF ± ICSI treatment, QOE not
applicable).
PCOS guideline translation program
A comprehensive, international translation and dissemination program
is currently underway to disseminate, translate and amplify the impact
of the International Evidence-based Guideline on the Assessment and
Management of Polycystic Ovary Syndrome. The program is inclusive
of a range of practice support tools including a GP tool, care plan, a set
of five algorithms (available at; https://www.monash.edu/medicine/
sphpm/mchri/pcos/resources/practice-tools-for-health-practitioners),
and resources to increase the PCOS related health literacy of consu-
mers (Fig. 2 PCOS consumer information graphic—PCOS fertility and
pregnancy) (available at; https://www.monash.edu/medicine/sphpm/
mchri/pcos/resources/resources-for-women-with-pcos). In addition,
the first evidence-based PCOS App (AskPCOS) (Fig. 3 Screens shots of
the PCOS App—AskPCOS) has been developed and now available for
purchase at iTunes. AskPCOS has a range of innovative features includ-
ing a self-diagnostic quiz, a comprehensive repository of information on
PCOS, a range of info-graphics, videos by experts, and a question
prompt list to build health practitioner interaction skills
The comprehensive evidence reviews, profiles and GRADE frame-
works supporting each recommendation, can be found in the supple-
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